BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,090 filers reported holding BAXTER INTL INC in Q2 2021. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $602,000 | -30.2% | 11,185 | -16.8% | 0.09% | -13.7% |
Q2 2022 | $863,000 | -17.2% | 13,438 | 0.0% | 0.10% | -1.9% |
Q1 2022 | $1,042,000 | -0.8% | 13,438 | +9.9% | 0.10% | +25.3% |
Q4 2021 | $1,050,000 | +3.0% | 12,227 | -3.5% | 0.08% | -4.6% |
Q3 2021 | $1,019,000 | -0.1% | 12,668 | 0.0% | 0.09% | +4.8% |
Q2 2021 | $1,020,000 | -9.8% | 12,668 | -5.5% | 0.08% | -13.5% |
Q1 2021 | $1,131,000 | +5.1% | 13,412 | 0.0% | 0.10% | -11.9% |
Q4 2020 | $1,076,000 | -3.5% | 13,412 | -3.2% | 0.11% | -9.2% |
Q3 2020 | $1,115,000 | -65.8% | 13,861 | -63.4% | 0.12% | -33.7% |
Q2 2020 | $3,265,000 | +0.2% | 37,918 | -5.6% | 0.18% | -11.3% |
Q1 2020 | $3,260,000 | -4.0% | 40,147 | -1.2% | 0.20% | +22.9% |
Q4 2019 | $3,396,000 | -5.7% | 40,618 | -1.3% | 0.17% | -13.1% |
Q3 2019 | $3,600,000 | +6.8% | 41,157 | 0.0% | 0.19% | +7.3% |
Q2 2019 | $3,371,000 | -1.4% | 41,157 | -2.1% | 0.18% | +3.5% |
Q1 2019 | $3,420,000 | +23.6% | 42,059 | 0.0% | 0.17% | +6.2% |
Q4 2018 | $2,768,000 | -14.6% | 42,059 | 0.0% | 0.16% | -1.2% |
Q3 2018 | $3,242,000 | +4.4% | 42,059 | 0.0% | 0.16% | -3.0% |
Q2 2018 | $3,106,000 | +16.2% | 42,059 | +2.3% | 0.17% | +14.2% |
Q1 2018 | $2,673,000 | -1.3% | 41,098 | -1.9% | 0.15% | -1.3% |
Q4 2017 | $2,708,000 | – | 41,899 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
13D Management LLC | 194,807 | $11,794,000 | 4.18% |
Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |